Annexon, Inc. (ANNX) - Multiplikator Forward P/S
Anticipation of the Phase 3 clinical trial results is driving volatility, where the current value of reflects market optimism for Annexon, Inc. (ANNX). The forward revenue multiple illustrates the demand for the unique blocking of the C1q protein to combat tissue degeneration. An innovative complement therapy platform provides the foundation for growth, establishing new treatment standards for Alzheimer's disease and rare autoimmune pathologies.
Rincian analitis perusahaan Annexon, Inc.
- rega saham lan target rega konsensus:
- indikator kapitalisasi pasar:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas Annexon, Inc.|ANNX - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang modal Annexon, Inc.|ANNX - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Annexon Biosciences Inc.|ANNX - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Annexon|Indikator likuiditas cepet annexonbio.com
- data bathi bisnis lan rasio investasi:
ANNX - Bathi perusahaan|Bathi sing dikarepake Annexon, Inc.|ANNX - Pangali rega marang bathi|Pangali Forward P/E Annexon Inc.|ANNX - Rega marang bathi kanthi panyesuaian wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Annexon Biosciences Inc.|ANNX - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Annexon|ANNX - Bathi saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan annexonbio.com|ANNX - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Annexon, Inc.
- indikator dodolan lan pendapatan:
Analisis fundamental perusahaan:ANNX (Annexon)
Fundamental asset selection requires analyzing leading indicators to assess business value relative to future cash flows. This metric compares the market capitalization of Annexon, Inc. (ANNX) with expected sales volumes, which, given the high demand for complement inhibitors, allows for an assessment of capitalization potential via the company's modeled P/S ratio as drugs enter the market following regulatory approval.
Analisis pesaing Annexon, Inc.
Biogen - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan NBIX|Regencell - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Axsome Corp AXSM|ACADIA Pharmaceuticals (ACAD) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan XENE|VKTX (Viking Therapeutics, Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Supernus Pharmaceuticals, Inc. (SUPN)|Multiplikator forward rega marang pendapatan CPRX (Catalyst Pharmaceuticals Inc)|Rasio kapitalisasi marang dodolan sing dikarepake Denali Corp|Multiplikator Forward P/S HRMY (Harmony Biosciences)|Multiplikator Forward P/S biohavenpharma.com BHVN|AMLX - Rasio rega marang prakiraan pendapatan|TRVI (Trevi Therapeutics Inc) - Kapitalisasi marang prakiraan pendapatan|Praxis Medicines (PRAX) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan AVXL|Multiplikator forward rega marang pendapatan CBLL|Kapitalisasi marang prakiraan pendapatan PRTA (Prothena Corporation)|Rasio rega marang prakiraan pendapatan Alector, Inc. (ALEC)|omeros.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S NGNE (Neurogene Corp)|AC Immune Inc (ACIU) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|VYGR: Multiplikator forward rega marang pendapatan|NMRA - Multiplikator Forward P/S|Scilex (SCLX) - Rasio rega marang prakiraan pendapatan|Tevogen Bio Holdings Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Alpha Cognition Inc|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Cognition Therapeutics Inc. CGTX|Multiplikator Forward P/S IKT|Multiplikator Forward P/S cassavasciences.com (SAVA)|Rasio rega marang prakiraan pendapatan Assertio ASRT|COYA: Kapitalisasi marang prakiraan pendapatan|VTGN - Rasio rega marang prakiraan pendapatan|OVID (Ovid Therapeutics Inc.) - Kapitalisasi marang prakiraan pendapatan|ABOS: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep cervomed.com (CRVO)|Multiplikator forward rega marang pendapatan ATHE|Kapitalisasi marang prakiraan pendapatan CLNN (Clene Nanomedicine)|Rasio rega marang prakiraan pendapatan PepGen Inc. (PEPG)|JUNS - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Relmada Therapeutics RLMD|ANVS: Kapitalisasi marang prakiraan pendapatan|GRCE: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan AIFF (Firefly Neuroscience, Inc.)|KLTO: Multiplikator Forward P/S|NRSN - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Reviva Pharmaceuticals|Kapitalisasi marang prakiraan pendapatan MTVA (MetaVia, Inc.)|Multiplikator Forward P/S NRXS|Multiplikator forward rega marang pendapatan heliusmedical.com HSDT|Passage Bio - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Neuphoria Therapeutics, Inc. (NEUP)|Minerva Neurosciences - Multiplikator Forward P/S|ATHA - Multiplikator Forward P/S|Addex Therapeutics Ltd (ADXN) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan ALZN|Rasio rega marang prakiraan pendapatan Cyclerion Therapeutics Inc.|Kapitalisasi marang prakiraan pendapatan PTIX (Protagenic)|Multiplikator forward rega marang pendapatan KTTA (Pasithea Therapeutics)|cortigent.com - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Avenue Therapeutics, Inc. ATXI|BCLI: Kapitalisasi marang prakiraan pendapatan|Cara Therapeutics, Inc - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Chromocell|ELYM (eliemtx.com) - Multiplikator forward rega marang pendapatan|Intra-Cellular Therapies, Inc. (ITCI) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Longboard Pharmaceuticals, Inc.|MRNS: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan NKGen (NKGN)|NRBO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S SAGE (Sage Therapeutics, Inc.)|Multiplikator Forward P/S synaptogen.com SNPX|TRVN - Rasio rega marang prakiraan pendapatan|VIGL (Vigil Neuroscience) - Kapitalisasi marang prakiraan pendapatan|Anew Medical (WENA) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan CERE
